Tuberculosis and COVID-19 co-infection: description of the global cohort

Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European respiratory journal Jg. 59; H. 3
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.03.2022
Schlagworte:
ISSN:1399-3003, 1399-3003
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
AbstractList Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes.BACKGROUNDInformation on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes.We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).METHODSWe enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality.RESULTSOf 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality.The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.CONCLUSIONThe data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34764184$$D View this record in MEDLINE/PubMed
BookMark eNpNj8tOwzAQRS0Eog_4AiSUJRsXjx-xzQ6VRytV6qawjWJ7QoPSuMTJgr-nFUViNXeOjkZzJ-S8jS0ScgNsBmDEPQhrBWNixrgShnLG4YyMj5Qe8fm_PCKTlD4Zg1wKuCQjIXUuwcgxWWwGh50fmpjqlJVtyObr9-UTBZv5SOu2Qt_XsX3IAibf1fvjksUq67eYfTTRlc3B28auvyIXVdkkvD7NKXl7ed7MF3S1fl3OH1fUS616qvDwtDdGQbDglQ4B0GGwpRPMSpYLib4yObAQtHKW5U4x4NpWxgWpreBTcvd7d9_FrwFTX-zq5LFpyhbjkAqurJZGaMYP6u1JHdwOQ7Hv6l3ZfRd_7fkPV7Zcig
CitedBy_id crossref_primary_10_2147_IDR_S346375
crossref_primary_10_1183_13993003_00925_2023
crossref_primary_10_1192_bji_2023_3
crossref_primary_10_1186_s12879_024_09395_w
crossref_primary_10_1080_14760584_2024_2425283
crossref_primary_10_3389_fcimb_2022_888582
crossref_primary_10_3389_fmed_2025_1582726
crossref_primary_10_4236_aid_2025_153032
crossref_primary_10_4103_ijmy_ijmy_189_23
crossref_primary_10_15446_revfacmed_v72n1_109537
crossref_primary_10_1002_iid3_1275
crossref_primary_10_1016_j_pulmoe_2023_05_008
crossref_primary_10_1007_s12038_025_00496_5
crossref_primary_10_3390_tropicalmed7110367
crossref_primary_10_52692_1857_0011_2023_3_77_08
crossref_primary_10_1016_j_pulmoe_2022_01_018
crossref_primary_10_3389_fphar_2022_1065124
crossref_primary_10_1183_13993003_02396_2022
crossref_primary_10_5588_ijtldopen_24_0035
crossref_primary_10_2147_IDR_S524300
crossref_primary_10_3390_jcm14082782
crossref_primary_10_1016_j_arbres_2022_07_013
crossref_primary_10_1093_ije_dyad012
crossref_primary_10_1186_s12879_024_09947_0
crossref_primary_10_1136_bmjopen_2023_080623
crossref_primary_10_5588_ijtldopen_25_0016
crossref_primary_10_1016_j_pulmoe_2022_01_015
crossref_primary_10_1016_j_pulmoe_2023_07_002
crossref_primary_10_3389_fmed_2024_1416197
crossref_primary_10_1183_20734735_0176_2021
crossref_primary_10_3389_fimmu_2023_1223260
crossref_primary_10_3389_fmed_2022_971008
crossref_primary_10_1016_j_jiph_2024_102511
crossref_primary_10_3389_fpubh_2025_1543647
crossref_primary_10_3390_v15010175
crossref_primary_10_7717_peerj_18041
crossref_primary_10_1371_journal_pgph_0004471
crossref_primary_10_7759_cureus_46353
crossref_primary_10_1016_j_sciaf_2025_e02680
crossref_primary_10_1002_ppul_27232
crossref_primary_10_3389_fimmu_2023_1244556
crossref_primary_10_3390_app15105423
crossref_primary_10_1590_s1678_9946202466065
crossref_primary_10_3390_idr17010011
crossref_primary_10_12688_wellcomeopenres_19275_2
crossref_primary_10_3346_jkms_2025_40_e38
crossref_primary_10_12688_wellcomeopenres_19275_1
crossref_primary_10_2147_JMDH_S463859
crossref_primary_10_3390_v16020260
crossref_primary_10_3389_fcimb_2023_1273019
crossref_primary_10_4103_ijmy_ijmy_19_24
crossref_primary_10_7759_cureus_44857
crossref_primary_10_3389_fimmu_2023_1250198
crossref_primary_10_3390_microorganisms11092277
crossref_primary_10_1007_s40808_022_01430_6
crossref_primary_10_1183_13993003_00493_2022
crossref_primary_10_1142_S0218348X25400997
crossref_primary_10_3390_microorganisms11092191
crossref_primary_10_3390_ijms24119670
crossref_primary_10_1186_s12879_023_08412_8
crossref_primary_10_1016_j_arbres_2023_09_002
crossref_primary_10_3389_fpubh_2024_1413604
crossref_primary_10_3389_fimmu_2023_1292486
crossref_primary_10_3389_fmed_2025_1554723
crossref_primary_10_3389_fpubh_2023_1247661
crossref_primary_10_3389_fpubh_2023_1117101
crossref_primary_10_2147_IDR_S370837
crossref_primary_10_1183_13993003_00149_2022
crossref_primary_10_3389_fmicb_2022_1061879
crossref_primary_10_3389_fpubh_2023_1226980
ContentType Journal Article
Copyright Copyright ©The authors 2022.
Copyright_xml – notice: Copyright ©The authors 2022.
CorporateAuthor TB/COVID-19 Global Study Group
CorporateAuthor_xml – name: TB/COVID-19 Global Study Group
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1183/13993003.02538-2021
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3003
ExternalDocumentID 34764184
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AAFWJ
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CGR
COF
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
NPM
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
7X8
ID FETCH-LOGICAL-c475t-5e993c8851d91c57dd1ebed9ab30940634ecf8610dd75b906b501279f8bd47932
IEDL.DBID 7X8
ISICitedReferencesCount 113
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000792497500022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1399-3003
IngestDate Sat Nov 01 14:33:32 EDT 2025
Thu Aug 28 04:23:13 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License Copyright ©The authors 2022.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c475t-5e993c8851d91c57dd1ebed9ab30940634ecf8610dd75b906b501279f8bd47932
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://erj.ersjournals.com/content/erj/59/3/2102538.full.pdf
PMID 34764184
PQID 2597483702
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2597483702
pubmed_primary_34764184
PublicationCentury 2000
PublicationDate 2022-03-01
PublicationDateYYYYMMDD 2022-03-01
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2022
References 35450921 - Eur Respir J. 2022 Apr 21;59(4):2200493. doi: 10.1183/13993003.00493-2022.
References_xml – reference: 35450921 - Eur Respir J. 2022 Apr 21;59(4):2200493. doi: 10.1183/13993003.00493-2022.
SSID ssj0016431
Score 2.6451628
Snippet Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
SubjectTerms Cohort Studies
Coinfection - epidemiology
COVID-19
Humans
Male
Prospective Studies
Tuberculosis - complications
Tuberculosis - epidemiology
Title Tuberculosis and COVID-19 co-infection: description of the global cohort
URI https://www.ncbi.nlm.nih.gov/pubmed/34764184
https://www.proquest.com/docview/2597483702
Volume 59
WOSCitedRecordID wos000792497500022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6ttlNurteRKqlgq09VOmtJDu7UJCkNq2_350ktSdB8JLDQiCZTGa-mW8ehNzESjmpbMAAO2RCISMWc-dYEnInmnGkedko_CL7fTUa6UGVcMurssqlTSwMNWQGc-QNjsgXJ7Xw--knw61RyK5WKzTWSU14KINaLUcrFsF72zLg0sjvN0U1dchrcQPP8OjW-3yBusKD3zFm4Ws6u_99yj2yU6FM-lCqxT5Zs-kB2epVPPoh6Q4XiZ2ZxUeWT3Iap0Dbr-_PjyzQ1GRsWaCV3lGwP2aFZo56tEjLESIUN-vO5kfkrfM0bHdZtVOBmVBGcxZZ_95GeZwFOjCRBAj8ZwQdJwIn6bVEaI1THlMByCjRzVYSITmtnUoAk3D8mGykWWpPCW3pODYq8TFuxEMBoQIDTjotgQOopqqT66WMxl5nkYiIU5st8vFKSnVyUgp6PC2Ha4xFKFuhDzvP_nD3Odnm2I1QlIRdkJrzf6y9JJvmaz7JZ1eFMvhrf9D7BjsIu8s
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tuberculosis+and+COVID-19+co-infection%3A+description+of+the+global+cohort&rft.jtitle=The+European+respiratory+journal&rft.date=2022-03-01&rft.issn=1399-3003&rft.eissn=1399-3003&rft.volume=59&rft.issue=3&rft_id=info:doi/10.1183%2F13993003.02538-2021&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1399-3003&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1399-3003&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1399-3003&client=summon